Biotech CSL NPAT rises 11%

Company News

by Rachael Jones

Biotech CSL (ASX:CSL) report their Net Profit After Tax US$1.9 billion up 11 per cent on the prior corresponding period US$1.7 billion.

The company has seen increased demand for its blood-based therapies - immunoglobulin and albumin therapies.

Seasonal flu vaccine sales also increased in demand.

Total revenue $8.5 billion from last year's $7.9 billion.

Final dividend was a rise on last year's 93 US cents to US$1:00.

Shares in CSL (ASX:CSL) are trading 6.8 per cent higher at $234.42
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.